scholarly article | Q13442814 |
P2093 | author name string | Sanjiv J Shah | |
Ravi B Patel | |||
P2860 | cites work | Visceral Adipose Tissue Drives Cardiac Aging Through Modulation of Fibroblast Senescence by Osteopontin Production. | Q51745075 |
Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. | Q52900479 | ||
Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. | Q53532447 | ||
Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. | Q54406123 | ||
Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. | Q54960430 | ||
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD) | Q59192167 | ||
Cardiomyocyte Stiffness in Diastolic Heart Failure | Q62476659 | ||
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension | Q70533705 | ||
Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction | Q86421869 | ||
Heart failure: Macrophages promote cardiac fibrosis and diastolic dysfunction | Q87919221 | ||
Heart failure: Histone deacetylases and diastolic dysfunction | Q87919223 | ||
Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction | Q89748582 | ||
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease | Q24323316 | ||
Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? | Q26765931 | ||
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation | Q26850196 | ||
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction | Q27024279 | ||
The case for inhibiting p38 mitogen-activated protein kinase in heart failure | Q28080674 | ||
Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? | Q28088503 | ||
Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
Trends in prevalence and outcome of heart failure with preserved ejection fraction | Q28252937 | ||
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. | Q30358659 | ||
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study | Q33589713 | ||
TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation | Q33793939 | ||
Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury | Q33873592 | ||
FGF23 induces left ventricular hypertrophy | Q34028891 | ||
Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". | Q49203906 | ||
Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated with Heart Failure and Preserved or Reduced Ejection Fraction. | Q49791521 | ||
Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. | Q50045909 | ||
Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment | Q50093822 | ||
Metformin and thiazolidinedione use in Medicare patients with heart failure | Q34210642 | ||
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis | Q34316944 | ||
Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. | Q34409745 | ||
Spironolactone for heart failure with preserved ejection fraction | Q34414462 | ||
Advanced glycation end products: sparking the development of diabetic vascular injury | Q34555042 | ||
Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis | Q34625372 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction | Q34873552 | ||
Irbesartan in patients with heart failure and preserved ejection fraction | Q34877640 | ||
Phenomapping for novel classification of heart failure with preserved ejection fraction | Q34995857 | ||
Right heart dysfunction in heart failure with preserved ejection fraction | Q35588220 | ||
Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export | Q35837234 | ||
Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue | Q35882942 | ||
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. | Q36104887 | ||
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction | Q36459987 | ||
Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure | Q36550830 | ||
The Failing Heart Relies on Ketone Bodies as a Fuel | Q36614537 | ||
Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease | Q36615734 | ||
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives | Q36682182 | ||
Overview of PDEs and their regulation | Q36739122 | ||
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study) | Q36985609 | ||
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. | Q37058596 | ||
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial | Q37328507 | ||
Coassembly of Mgm1 isoforms requires cardiolipin and mediates mitochondrial inner membrane fusion | Q37365417 | ||
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis | Q37580301 | ||
Expert consensus document: Mitochondrial function as a therapeutic target in heart failure | Q37699474 | ||
Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. | Q38110226 | ||
Gigantic business: titin properties and function through thick and thin | Q38195698 | ||
The pathophysiology of heart failure with preserved ejection fraction. | Q38222648 | ||
Targeting interleukin-1 in heart failure and inflammatory heart disease | Q38260179 | ||
INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design | Q38377133 | ||
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial | Q38389314 | ||
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial | Q38394069 | ||
Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction | Q38413616 | ||
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. | Q38420677 | ||
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study | Q38488882 | ||
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 | ||
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review | Q38658569 | ||
Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. | Q38667037 | ||
Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure | Q38678461 | ||
Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction | Q38691846 | ||
Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation | Q38727741 | ||
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics | Q38806909 | ||
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus | Q38827756 | ||
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. | Q38872061 | ||
Partial Adenosine A1 Agonist in Heart Failure | Q38988016 | ||
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Q39405472 | ||
Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation | Q40286144 | ||
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil | Q41242943 | ||
Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure | Q41874182 | ||
Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance | Q42062803 | ||
Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction. | Q42382004 | ||
PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways. | Q42454314 | ||
Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation | Q42752870 | ||
Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes | Q43269097 | ||
Getting to the "Heart" of Cardiac Disease by Decreasing Mitochondrial Iron. | Q43288665 | ||
Anti-aldosteronergic effect of torasemide | Q44265911 | ||
Molecular mechanism of levosimendan action: an update | Q44580510 | ||
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Q44588075 | ||
RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study | Q44596273 | ||
Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). | Q45058507 | ||
Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. | Q45921765 | ||
Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. | Q45947184 | ||
Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Tria | Q45999393 | ||
Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. | Q46140653 | ||
Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease | Q46259496 | ||
Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure | Q46556129 | ||
Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy | Q46850755 | ||
Osteopontin expression is required for myofibroblast differentiation | Q46850865 | ||
Functional and structural alterations of cardiac and skeletal muscle mitochondria in heart failure patients | Q46915783 | ||
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials | Q47614541 | ||
Inflammation in Heart Failure With Preserved Ejection Fraction: Time to Put Out the Fire | Q47716060 | ||
Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction | Q47755913 | ||
Cardiac macrophages promote diastolic dysfunction. | Q48232420 | ||
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial | Q48395213 | ||
Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. | Q48414650 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | heart failure | Q181754 |
ejection fraction | Q641303 | ||
Heart failure with preserved ejection fraction | Q3799239 | ||
P304 | page(s) | 41-63 | |
P577 | publication date | 2018-10-08 | |
P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
P1476 | title | Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials | |
P478 | volume | 59 |